Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial

J Infect Dis. 1993 Nov;168(5):1304-7. doi: 10.1093/infdis/168.5.1304.

Abstract

The role of ciprofloxacin and trimethoprim-sulfamethoxazole (TMP-SMZ) was evaluated in empiric treatment of uncomplicated Salmonella enteritis in a comparative, double-blind trial. Patients were randomized to receive ciprofloxacin (500 mg), TMP-SMZ (160/800 mg), or placebo orally twice daily for 5 days. There were 65 evaluatable patients with acute, uncomplicated, culture-confirmed Salmonella enteritis. Duration of diarrhea, abdominal pain, or vomiting and time to defervescence were not significantly different for patients treated with ciprofloxacin, TMP-SMZ, or placebo; there also were no significant differences with respect to full resolution of symptoms for ciprofloxacin versus placebo (point estimate, 0.2 days; 95% confidence interval [CI], -0.5 to 0.9 days) or for TMP-SMZ versus placebo (point estimate, 0.2 days; 95% CI, -1.0 to 0.6 days). The rate of clearance of salmonellae from stools was not significantly different among the groups.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Ciprofloxacin / therapeutic use*
  • Double-Blind Method
  • Drug Combinations
  • Enteritis / drug therapy*
  • Feces / microbiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Salmonella Infections / drug therapy*
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*

Substances

  • Drug Combinations
  • Ciprofloxacin
  • Trimethoprim, Sulfamethoxazole Drug Combination